FdaApplication
NDA 215859
Identifiers
- fda_app_no: NDA215859
Properties
| Property | Value |
|---|---|
| applicant_name | JANSSEN PHARMACEUTICALS INC |
| application_type | NDA |
| approval_date | 2021-12-20 |
Revenue by product
XARELTO
| Period | Revenue |
|---|---|
| Q2 2026 | $664.0M |
| Q1 2026 | $642.0M |
| Q4 2025 | $687.0M |
| Q3 2025 | $635.0M |
| Q2 2025 | $621.0M |
| Q1 2025 | $690.0M |
| Q4 2024 | $676.0M |
| Q3 2024 | $592.0M |
| Q2 2024 | $587.0M |
| Q1 2024 | $518.0M |
| Q4 2023 | $525.0M |
| Q3 2023 | $625.0M |
| Q2 2023 | $637.0M |
| Q1 2023 | $578.0M |
| Q4 2022 | $667.0M |
| Q3 2022 | $689.0M |
| Q2 2022 | $609.0M |
| Q1 2022 | $508.0M |
| Q4 2021 | $644.0M |
| Q3 2021 | $636.0M |
| Q2 2021 | $569.0M |
| Q1 2021 | $589.0M |
| Q4 2020 | $629.0M |
| Q3 2020 | $630.0M |
| Q2 2020 | $559.0M |
| Q1 2020 | $527.0M |
| Q4 2019 | $609.0M |
| Q3 2019 | $613.0M |
| Q2 2019 | $549.0M |
| Q1 2019 | $542.0M |
| Q4 2018 | $608.0M |
| Q3 2018 | $612.0M |
| Q2 2018 | $679.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| XARELTO | RIVAROXABAN | 1MG/ML | FOR SUSPENSION;ORAL |
1 product